CPRX
CATALYST PHARMACEUTICALS, INC.Price
Daily candles with volume.
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells since Jul 15. Recent filings are awards, exercises and tax withholding.
- InstitutionsBEARISH
Q3 2026: 1 added (0 new), 33 trimmed or exited.
- EstimatesRISING
Current-quarter EPS estimate $0.675 → $0.736 over 90 days. 1 up, 0 down in 30 days.
- Short sellersCOVERING
Short interest −95.7% to 340.3K shares. 1.0 days to cover, ≈0.3% of shares.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| Swedbank AB | EXIT | $0.00 |
| PRINCIPAL FINANCIAL GROUP INC | EXIT | $0.00 |
| DIMENSIONAL FUND ADVISORS LP | EXIT | $0.00 |
| Bank of New York Mellon Corp | EXIT | $0.00 |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | EXIT | $0.00 |
| GEODE CAPITAL MANAGEMENT, LLC | EXIT | $0.00 |
| ROYCE & ASSOCIATES LP | EXIT | $0.00 |
| Nuveen, LLC | EXIT | $0.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action May 2026| Date | Firm | Rating |
|---|---|---|
| May 28, 2026 | HC Wainwright & Co. DOWNGRADE | Neutral |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
DENKHAUS DONALD A Director Jul 15, 2026 | TO ISSUER | 20,000 sh |
DENKHAUS DONALD A Director Jul 15, 2026 | TO ISSUER | $15.7M |
DENKHAUS DONALD A Director Jul 15, 2026 | TO ISSUER | 33,500 sh |
DENKHAUS DONALD A Director Jul 15, 2026 | TO ISSUER | 15,000 sh |
DENKHAUS DONALD A Director Jul 15, 2026 | TO ISSUER | 23,248 sh |
Tierney David S Director Jul 15, 2026 | TO ISSUER | 33,500 sh |
Tierney David S Director Jul 15, 2026 | TO ISSUER | 18,115 sh |
DENKHAUS DONALD A Director Jul 15, 2026 | TO ISSUER | 30,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $0.74 | $0.74–$0.74 | +6.3% | $154.6M |
| Current FY | $3.17 | $3.17–$3.17 | +11.0% | $636.2M |
| Next FY | $3.18 | $2.58–$3.55 | +1.5% | $717.9M |
| Next Q | $0.82 | $0.82–$0.82 | +12.1% | $162.1M |
Short side
FINRA· Jul 15, 2026| Jul 14, 2026 | Deletion | Resumed |
SecBot reports
16 filings · 6 bullish · 5 bearish · 1 mixed · 4 neutral- BEARISH INST-CLUSTERNov 4, 2026
Three institutional investors, Swedbank Ab, Principal Financial Group, and Dimensional Fund…
Monitor upcoming Catalyst Pharmaceuticals earnings or press releases for potential negative catalysts (e.g., pipeline setback, regulatory issue, or competitive threat) that may have prompted these…
- MIXED INST-CLUSTERAug 22, 2026
CPRX saw a mixed institutional cluster in Q2 2026: 23 buyers added $226.9M in new positions (led…
The mixed cluster with heavy passive accumulation but active-manager distribution suggests no clear catalyst consensus. Monitor for insider buying or a catalyst (e.g., pipeline update, FDA decision)…
- BEARISH 15-12GJul 24, 2026
Catalyst Pharmaceuticals filed a Form 15-12G to terminate its SEC registration under Section…
CPRX common stock is now effectively worthless as a public security, the delisting and deregistration sequence means no exchange trading and no SEC reporting. Existing shareholders should expect…
- BEARISH EFFECTJul 17, 2026
Catalyst Pharmaceuticals received SEC effectiveness on July 16, 2026 for four separate shelf…
The simultaneous effectiveness of multiple shelf registrations signals Catalyst is prepared to raise capital at any time. Monitor for a subsequent prospectus supplement or 424B filing that would…
All CPRX filing & press-release reports (16)
- INST-CLUSTER reportNov 4, 2026
- INST-CLUSTER reportAug 22, 2026
- 15-12G reportJul 24, 2026
- EFFECT reportJul 17, 2026
- 25-NSE reportJul 15, 2026
- 8-K reportJul 8, 2026
- 8-K reportJun 30, 2026
- DEFA14A reportJun 30, 2026
- PREM14A reportMay 28, 2026
- DEFA14A reportMay 12, 2026
- PRESS-RELEASE reportMay 11, 2026
- DEFA14A reportMay 7, 2026
- DEFA14A reportMay 7, 2026
- 8-K reportMay 7, 2026
- 8-K/A reportMar 19, 2026
- 8-K reportFeb 25, 2026